首药控股(688197) - 2025 Q3 - 季度财报

Revenue and Profit - Total revenue for the year-to-date period was CNY 2,000,000, representing a decrease of 47.37% compared to the same period last year[3] - The total profit for the third quarter was a loss of CNY 50,395,389.71, with a year-to-date loss of CNY 154,767,127.09[3] - The net profit attributable to shareholders for the third quarter was a loss of CNY 50,395,389.71, with a year-to-date loss of CNY 154,767,127.09[3] - Total operating revenue for the first three quarters of 2025 is CNY 2,000,000, a decrease of 47.37% compared to CNY 3,800,000 in the same period of 2024[20] - Net profit for the first three quarters of 2025 is a loss of CNY 154,767,127.09, an improvement compared to a loss of CNY 159,978,134.87 in the same period of 2024[22] - The company's net loss for the first three quarters of 2025 was CNY -154,748,613.41, slightly improved from CNY -159,738,947.54 in the same period of 2024[34] Expenses and Costs - Research and development expenses totaled CNY 47,099,795.86 for the quarter, a decrease of 17.28% year-over-year, and accounted for 7,763.48% of total revenue year-to-date, an increase of 3446.54 percentage points[5] - Total operating costs for the first three quarters of 2025 amount to CNY 170,147,424.42, down from CNY 175,955,688.19 in the previous year, reflecting a decrease of 4.59%[20] - Research and development expenses for the first three quarters of 2025 amounted to CNY 158,670,534.79, down from CNY 167,952,758.80 in 2024, reflecting a reduction of approximately 5.66%[33] - The cash outflow for purchasing goods and services was 42,118,155.76 RMB in 2025, significantly higher than 18,918,652.90 RMB in 2024, indicating increased costs[37] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 761,769,419.14, a decrease of 17.40% from the previous year[5] - The total assets of the company are 761,769,419.14 RMB, down from 922,228,105.25 RMB in the previous period[16] - The total liabilities amount to 107,040,215.45 RMB, slightly decreased from 110,540,459.78 RMB[16] - The company's total current assets as of September 30, 2025, amount to 691,066,446.18 RMB, a decrease from 779,798,182.90 RMB as of December 31, 2024[15] - The total liabilities amount to CNY 107,523,433.29, a decrease from CNY 113,214,992.31 in the previous year[18] - The total liabilities as of September 30, 2025, were CNY 112,643,230.05, compared to CNY 113,378,151.31 at the end of 2024, showing a slight decrease of 0.65%[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,146[11] - The largest shareholder, Li Wenjun, holds 72,953,101 shares, representing 49.05% of the total shares[11] - Total equity attributable to shareholders decreased to CNY 654,245,985.85 from CNY 809,013,112.94 year-over-year[18] - The company's total equity decreased to CNY 655,448,127.34 from CNY 810,196,740.75, reflecting a decline of 19.14%[31] Cash Flow - The net cash flow from operating activities for the third quarter was -CNY 58,785,348.02, with a year-to-date total of -CNY 172,409,965.55[3] - Cash flow from operating activities for the first three quarters of 2025 shows a net outflow of CNY -172,409,965.55, worsening from CNY -144,235,376.10 in the same period of 2024[26] - The net cash flow from financing activities was CNY -3,679,812.08, compared to CNY -4,156,496.35 in the previous period, indicating an improvement of 11.48%[27] - The cash and cash equivalents at the end of the reporting period were CNY 6,324,610.99, down from CNY 83,350,249.11 at the end of 2024, a decrease of 92.39%[27] - The cash inflow from other operating activities was 1,651,062.14 RMB in 2025, compared to 5,501,338.30 RMB in 2024, reflecting a decrease in operational cash inflows[37] Investment Performance - Cash inflow from investment activities in the first three quarters of 2025 is CNY 2,577,141,184.02, compared to CNY 1,399,229,624.57 in the previous year, indicating a significant increase[26] - Cash outflow from investment activities for the first three quarters of 2025 is CNY 2,417,461,537.68, up from CNY 1,697,827,898.31 in the same period of 2024[26] - The company reported a significant increase in investment income, reaching CNY 6,756,262.57 in the first three quarters of 2025, compared to CNY 3,088,773.73 in the same period of 2024[21] - The company reported a cash inflow from investment income of 17,685,093.31 RMB in 2025, up from 10,243,196.74 RMB in 2024, showing improved investment performance[37] Accounting Standards - The company has not yet adopted the new accounting standards starting from 2025, which may impact future financial reporting[38]